133 related articles for article (PubMed ID: 38768766)
1. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability.
Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W
Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766
[TBL] [Abstract][Full Text] [Related]
2. Dipeptides as co-formers in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
[TBL] [Abstract][Full Text] [Related]
3. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
4. Aspartame as a co-former in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
[TBL] [Abstract][Full Text] [Related]
5. Poly (amino acid)s as new co-formers in amorphous solid dispersion.
Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W
Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970
[TBL] [Abstract][Full Text] [Related]
6. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
Wu W; Löbmann K; Rades T; Grohganz H
Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
[TBL] [Abstract][Full Text] [Related]
7. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization.
Zou Z; Huang Q; Li X; Liu X; Yin L; Zhao Y; Liang G; Wu W
Eur J Pharm Sci; 2023 Sep; 188():106526. PubMed ID: 37442486
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
9. Co-former selection for co-amorphous drug-amino acid formulations.
Kasten G; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
[TBL] [Abstract][Full Text] [Related]
10. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
11. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
12. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
[TBL] [Abstract][Full Text] [Related]
13. Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.
Han J; Wei Y; Lu Y; Wang R; Zhang J; Gao Y; Qian S
Expert Opin Drug Deliv; 2020 Oct; 17(10):1411-1435. PubMed ID: 32683996
[TBL] [Abstract][Full Text] [Related]
14. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.
Wu W; Ueda H; Löbmann K; Rades T; Grohganz H
Eur J Pharm Biopharm; 2018 Oct; 131():25-32. PubMed ID: 30040997
[TBL] [Abstract][Full Text] [Related]
15. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs.
Wang H; Zhao P; Ma R; Jia J; Fu Q
Drug Discov Today; 2024 Feb; 29(2):103883. PubMed ID: 38219970
[TBL] [Abstract][Full Text] [Related]
17. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
18. Formulation of co-amorphous systems from naproxen and naproxen sodium and in situ monitoring of physicochemical state changes during dissolution testing by Raman spectroscopy.
Ueda H; Peter Bøtker J; Edinger M; Löbmann K; Grohganz H; Müllertz A; Rades T; Østergaard J
Int J Pharm; 2020 Sep; 587():119662. PubMed ID: 32682958
[TBL] [Abstract][Full Text] [Related]
19. Predictive identification of co-formers in co-amorphous systems.
Chambers LI; Grohganz H; Palmelund H; Löbmann K; Rades T; Musa OM; Steed JW
Eur J Pharm Sci; 2021 Feb; 157():105636. PubMed ID: 33160046
[TBL] [Abstract][Full Text] [Related]
20. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
